)
Bruker (BRKR) investor relations material
Bruker 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic focus and financial outlook
Emphasis on profitability, margin expansion, and double-digit EPS growth through 2030, following a 70% revenue increase from 2020 to 2024 and a challenging 2025.
Targeting margin improvement from mid-teens to low/mid-20s, 250–300 basis points organic margin expansion in FY26, and $120 million in cost savings by 2026.
Project Accelerate 3.0 expands into aftermarket, sticky revenues, and new growth areas such as clinical microbiology, molecular diagnostics, and automated AI lab tools.
FY25 revenue guidance at ~$3.43 billion, up 2%, with flat to low single-digit organic growth expected in FY26.
Double-digit non-GAAP EPS CAGR targeted for FY27–30, with 200–300 bps above-market revenue CAGR.
Market and product developments
Significant investments and acquisitions in proteomics, metabolomics, spatial biology, and scientific software have transformed the portfolio for the post-genomic era.
New product launches in spatial biology (CosMx Whole Transcriptome Panel, CosMx 2.0, CellScape) and mass spectrometry (TIMS Omni, TIMS Metabo, timsOmni) are gaining traction, with strong consumables growth and early orders.
Automated, digitized, AI-ready lab tools now represent a $100 million business with high growth potential, targeting a $9–12 billion market with 15–25% CAGR.
Defense detection and semiconductor metrology businesses are growing, with defense tech expected to reach $100 million and YoY growth over 30%, and expanded tools for advanced packaging and AI chip production.
Large multi-year orders in superconductors and magnetic resonance support multi-year growth and remove previous headwinds.
Clinical microbiology and molecular diagnostics expansion
MALDI Biotyper platform has nearly 8,000 systems installed; expansion into rapid AST and syndromic panels for infectious disease diagnostics.
ELITechGroup acquisition boosts molecular diagnostics, now a $500 million business with high aftermarket revenue and margins; over 65% of microbiology and MDx revenue is recurring.
Plans to launch affordable syndromic panels and enter the U.S. market, with S2A MDx systems (InGenius, BeGenius) and clinical trials starting in 2026.
Addition of Wave Rapid AST platform, targeting FDA clearance and U.S. launch in 2026, expected to address a $400 million market for sepsis and antimicrobial resistance and further differentiate the clinical microbiology business.
Integration of rapid AST with ID solutions aims to revolutionize clinical microbiology workflows.
Next Bruker earnings date
Next Bruker earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)